12/16
08:06 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
11/25
06:21 pm
bbio
Rating for BBIO
Medium
Report
Rating for BBIO
11/25
06:21 pm
bbio
Rating for BBIO
Medium
Report
Rating for BBIO
11/15
12:10 pm
bbio
Rating for BBIO
Low
Report
Rating for BBIO
11/15
12:10 pm
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/25
08:37 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
10/17
10:41 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/16
10:00 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/16
10:00 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/16
08:44 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/16
08:44 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/3
08:17 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Oppenheimer Holdings Inc.. They set a "market perform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Oppenheimer Holdings Inc.. They set a "market perform" rating on the stock.
10/3
08:06 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/3
08:06 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
9/30
08:01 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.